Intellia reports Q4 net loss $132.2M; cash $1.0B; on track for Phase 3 NTLA-2001 in Q1 2024

Intellia Therapeutics, Inc.

2023-FY EPS reported -$5.42 revenue$36,275,000

Q4 2023 net loss $132.2M vs $113.4M YoY; R&D expenses rose $9.0M to $109.0M.
Cash, equivalents and securities $1.0B as of Dec 31, 2023; expected to fund operations into mid-2026.
On track to dose first patient in Phase 3 MAGNITUDE trial (NTLA-2001) for ATTR cardiomyopathy in Q1 2024.
Plan to initiate Phase 3 of NTLA-2002 for hereditary angioedema in 2H24; positive interim Phase 1 data published in NEJM.
Expanding pipeline: Phase 1 for NTLA-3001 (AATD) expected in 2024; collaboration with ReCode for cystic fibrosis.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Intellia Therapeutics, Inc. reported financial results for the fourth quarter and year ended December 31, 2023.

Period: the fourth quarter and year ended December 31, 2023
Result: reported results

Exact text from the filing

On February 22, 2024, Intellia Therapeutics, Inc. announced its financial results and business updates for the quarter and year ended December 31, 2023.

View on SEC.gov

Browse all earnings releases →

Intellia Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0000950170-24-018436

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.